Table 5.
Clinical characteristics of other adverse events
Etomidate group (n = 90) | Propofol group (n = 90) | P-value | Significance | ||
---|---|---|---|---|---|
During ERCP | Nausea-vomiting, n (%) | 2 (2.22) | 3 (3.33) | 1.000 | n.s. |
Myoclonus, n (%) | 2 (2.22) | 1 (1.11) | 1.000 | n.s. | |
Injection site pain, n (%) | 0 (0.00) | 6 (6.67) | 0.029 | * | |
After ERCP | Pancreatitis, n (%) | 1 (1.11) | 1 (1.11) | 1.000 | n.s. |
Cholangitis, n (%) | 3 (3.33) | 4 (4.44) | 1.000 | n.s. |
n.s.: no significance; *P<0.05.